Triple Combination DAAs for Treating HCV GT1b Subjects

Summary

There is only one kind of treatment (simeprevir 150 mg + sofosbuvir 400 mg+daclatasvir 60 mg) in this study but the treatment duration may be different depending on patients' response to the antiviral therapy and whether patients have liver cirrhosis. If patients have no cirrhosis and the HCV viral load on day 2 is \<500 IU/ml, patients will receive sofosbuvir, daclatasvir and simeprevir for 3 weeks, otherwise the treatment duration is 4 weeks. If patients have cirrhosis and the HCV viral load on day 2 is \<500 IU/ml, patients will receive sofosbuvir, daclatasvir and simeprevir for 6 weeks, otherwise the treatment duration will be 8 weeks.

Timeline

Start

2016-12

Primary completion

2017-12

Completion

2017-12

Outcome

Outcome not reported

Stopped: “The collaborating pharmaceutical company will not wish to continue with the trial due to the internal issues in the company.”

Drugs

Indications